198 related articles for article (PubMed ID: 22564836)
1. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints.
Arendrup MC; Pfaller MA;
Antimicrob Agents Chemother; 2012 Jul; 56(7):3965-8. PubMed ID: 22564836
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species.
Astvad KM; Perlin DS; Johansen HK; Jensen RH; Arendrup MC
Antimicrob Agents Chemother; 2013 Jan; 57(1):177-82. PubMed ID: 23089746
[TBL] [Abstract][Full Text] [Related]
5. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
[TBL] [Abstract][Full Text] [Related]
6. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Moet GJ; Jones RN
J Clin Microbiol; 2010 May; 48(5):1592-9. PubMed ID: 20335424
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates.
Arendrup MC; Park S; Brown S; Pfaller M; Perlin DS
Antimicrob Agents Chemother; 2011 May; 55(5):1891-5. PubMed ID: 21357293
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro susceptibility of clinical isolates of Candida paparsilosis complex and other Candida species to caspofungin and anidulafungin by Etest.
Khan Z; Ahmad S; Joseph L; Chandy R; Theyyathel A
J Chemother; 2011 Apr; 23(2):97-101. PubMed ID: 21571626
[TBL] [Abstract][Full Text] [Related]
10. Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria.
Aigner M; Erbeznik T; Gschwentner M; Lass-Flörl C
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559257
[No Abstract] [Full Text] [Related]
11. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
J Clin Microbiol; 2011 Feb; 49(2):624-9. PubMed ID: 21147948
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.
Eschenauer GA; Nguyen MH; Shoham S; Vazquez JA; Morris AJ; Pasculle WA; Kubin CJ; Klinker KP; Carver PL; Hanson KE; Chen S; Lam SW; Potoski BA; Clarke LG; Shields RK; Clancy CJ
Antimicrob Agents Chemother; 2014; 58(4):1897-906. PubMed ID: 24395235
[TBL] [Abstract][Full Text] [Related]
13. Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates.
Espinel-Ingroff A; Canton E; Peman J; Martín-Mazuelo E
Antimicrob Agents Chemother; 2010 Mar; 54(3):1347-50. PubMed ID: 20028814
[TBL] [Abstract][Full Text] [Related]
14. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Aug; 57(8):3528-35. PubMed ID: 23669387
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
[TBL] [Abstract][Full Text] [Related]
16. Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.
Pfaller MA; Messer SA; Diekema DJ; Jones RN; Castanheira M
J Clin Microbiol; 2014 Jan; 52(1):108-14. PubMed ID: 24153129
[TBL] [Abstract][Full Text] [Related]
17. Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.
Pfaller MA; Diekema DJ; Jones RN; Castanheira M
J Clin Microbiol; 2014 Sep; 52(9):3223-9. PubMed ID: 24951808
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Etest and a rapid flow cytometry-based method with the reference CLSI broth microdilution protocol M27-A3 for the echinocandin susceptibility testing of Candida spp.
Vale-Silva LA; Pinto P; Lopes V; Ramos H; Pinto E
Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):941-6. PubMed ID: 21909651
[TBL] [Abstract][Full Text] [Related]
19. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
Chen YC; Kuo SF; Chen FJ; Lee CH
Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
[TBL] [Abstract][Full Text] [Related]
20. Caspofungin disk diffusion breakpoints and quality control.
Brown SD; Traczewski MM
J Clin Microbiol; 2008 Jun; 46(6):1927-9. PubMed ID: 18400918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
